All In Biotech

Drug Trial Radar · NCT07773610

Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis

A Phase 2, Randomised, Controlled, Multicentre Two-Part Trial Assessing the Safety and Efficacy of TBAJ-587 as Part of a Combination Regimen in Newly Diagnosed, Drug-Sensitive, Sputum-Positive Pulmonary Tuberculosis

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Sep 25, 2026

Primary completion

Dec 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
TASK Applied ScienceAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2, two-part, multicentre, open label, controlled, randomised clinical trial in adult participants with newly diagnosed, sputum-positive pulmonary drug-sensitive tuberculosis (DSTB). Assessing the Safety and Efficacy of TBAJ-587 as Part of a Combination Regimen in Newly Diagnosed, Drug-Sensitive, Sputum-Positive Pulmonary Tuberculosis

Conditions

  • Tuberculosis, Pulmonary

Interventions

  • TBAJ-587 50 mgDrug

    TBAJ-587LD Tablet 50 mg 100 mg OD TBAJ-587HD Tablet 50 mg 200 mg OD TBAJ-587SD Tablet 50 mg Dose selected from Part A daily

  • Pretomanid 200mgDrug

    Pretomanid Tablet 200 mg 200 mg OD

  • Linezolid 600Mg TabDrug

    600 mg OD

  • BTZ-043 250 mg or 500 mgDrug

    1 000 mg OD

  • HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)Drug

    H 75 mg, R 150 mg, Z 400 mg, E 275 mg fixed dose combination

  • Quabodepistat (Q) 30 mgDrug

    30 mg OD

  • Ganfeborole 20 mgDrug

    20 mg OD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Change in Log10-Transformed Sputum Culture Time to Positivity From Baseline Through Week 8Time frame: From baseline to the end of treatment at 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TASK Brooklyn

    Cape Town, Western Cape, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.